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Efavirenzsing is mediated by protease (PR), with enzymatic activation triggered by Gag–
Pol/Gag–Pol interaction. We previously reported that truncation mutations at the reverse transcriptase (RT)
connection subdomain markedly impair virus particle processing, suggesting an important role for the RT
subdomain in PR-mediated virus processing. A highly conserved tryptophan (Trp) repeat motif of the HIV-1
RT connection subdomain is involved in RT dimerization. Our goal in this study was to determine whether
mutations at the Trp repeat motif have any effect on PR-mediated virus processing. Our results indicate that
even though alanine substitutions at W401 (W401A) or at both W401 and W402 (W401A/W402A) have no
major effect on steady-state virus processing, the combined W401A/W402A mutations partially negate and
the W401A mutation almost completely negates an efavirenz (EFV)-imposed barrier to virus production.
The combination of RT instability and poor enzymatic activity reﬂects a RT dimerization defect incurred by
the mutations. We also found that an artiﬁcial p66RT carrying the W401A or W401A/W402A mutations
was packaged into virions more efﬁciently than wild-type p66RT, and that the viral incorporation of p66RT
is signiﬁcantly reduced by EFV, implying a novel effect of EFV on RT–Gag interaction. Our results suggest
that the Trp repeat motif may play a role in the Gag–Pol/Gag–Pol interaction that contributes to subsequent
PR activation.
© 2008 Elsevier Inc. All rights reserved.Introduction
The retrovirus pol gene encodes a polyprotein Pol that comprises
required enzymes for virus replication. In most known retroviruses
(including HIV-1), Pol is synthesized as a Gag–Pol fusion protein and
packaged into virions via interaction with Gag through its N-terminal
Gag domain (Chien et al., 2006; Chiu et al., 2002; Halwani et al., 2003;
Huang and Martin, 1997; Smith et al., 1993; Srinivasakumar et al.,
1995). One known exception is human foamy virus (HFV) Pol, which is
packaged into virions without the need for Gag–Pol formation
(Lochelt and Flugel, 1996). However, results from efforts to coexpress
individual Gag and Pol from separate plasmids indicate that HIV-1 and
murine leukemia virus (MLV) Pol are both capable of being
incorporated into virus-like particles (VLPs) (Buchschacher et al.,
1999; Cen et al., 2004; Liao et al., 2007). Since HIV-1 pol and gag
reading frames partly overlap, Gag–Pol is normally translated by a −1
ribosomal frameshift event occurring at an approximate frequency of
5% during Gag translation, resulting in a 1:20 ratio of synthesized
Gag–Pol to Gag (Jacks et al., 1988). During or after virus budding, HIV-1search and Education, Taipei
ipei 11217, Taiwan. Fax: +886 2
l rights reserved.protease embedded in Gag–Pol is activated for the purpose of cleaving
Gag and Gag–Pol polyproteins. The processing of Gag precursor Pr55
results in four major products: matrix (MA; p17), capsid (CA; p24),
nucleocapsid (NC; p7) and p6 domain (Swanstrom andWills, 1997). In
addition to Gag products, Gag–Pol cleavage yields pol-derived
protease (PR), reverse transcriptase (RT), and integrase (IN). The
fully active RT heterodimer p66/p51 is thought to be derived from an
intermediate p66/p66 homodimer by removing the RNaseH sub-
domain (p15) from either one of the two p66RT molecules (di Marzo
Veronese et al., 1986).
How PR is activated tomediate virionmaturation is not completely
understood. Functional PR is in dimeric form; it is generally believed
that PR activation is triggered during Gag–Pol/Gag–Pol interaction or
Gag–Pol multimerization. Accordingly, mutations that potentially
affect the Gag–Pol/Gag–Pol interaction process may affect PR activa-
tion (Louis et al., 1994). This hypothesis is supported by several
independent studies demonstrating that sequence mutations either
upstream or downstream of PR can lead to markedly impaired PR
activity or PR-mediated virus maturation (Bukovsky and Gottlinger,
1996; Chiu et al., 2002; Liao and Wang, 2004; Quillent et al., 1996;
Zybarth and Carter, 1995). Since functionally active RT is also dimeric,
domains involved in RT–RT interaction are assumed to contribute
to PR activation by promoting Gag–Pol multimerization. Whether
or not RT–RT interactions between Gag–Pol molecules contribute
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pieces of evidence suggest that the RT sequence plays a crucial role in
determining PR activity: (a) HIV-1 mutants with RT truncation
mutations are defective in PR-mediated Gag processing (Liao and
Wang, 2004; Quillent et al., 1996); and (b) efavirenz (EFV), a non-
nucleoside reverse transcriptase inhibitor (NNRTI) that promotes RT
subunit association in vitro (Tachedjian et al., 2001; Venezia et al.,
2006), is capable of reducing virus particle release by enhancing PR-
mediated Gag and Gag–Pol cleavage (Figueiredo et al., 2006;
Tachedjian et al., 2005a).
Regarding the sequence involved in HIV-1 RT–RT interaction, a
hydrophobic cluster consisting of 6 tryptophan (Trp) residues has
been identiﬁed in the connection subdomain of the HIV-1 RT subunit
(codons 398 to 414). This highly conserved Trp repeat motif is also
found in primate lentiviral reverse transcriptases (Baillon et al., 1991).
In vitro studies have demonstrated that substitution mutations in Trp
repeat motif residues result in impaired RT dimerization (Mulky et al.,
2005; Tachedjian et al., 2003), suggesting a motif role in RT–RT
interactions. Given that effective RT–RT interactions enhance PR-
mediated Gag processing, Trp repeat motif mutations may result in
impaired PR-mediated virus maturation (Wapling et al., 2005).
Consistent with this hypothesis, we previously reported that HIV-1
mutants with deletions in the RT connection subdomain that includes
the Trp repeat motif are markedly defective in virus particle
maturation (Liao and Wang, 2004). However, the extent to which
the RT domain contributes to PR-mediated Gag and Gag–Pol
processing has not been completely deﬁned. One hypothesis is thatFig. 1. Assembly and processing of HIV-1 Gag in the presence of efavirenz and/or HIV-1 prote
18 h post-transfection, transfectants from two 10 cm culture dishes were pooled, split equally
5 μM HIV-1 protease inhibitor (PI) Ro31-8959. At 4 h, culture supernatant was removed a
replacement, cells and supernatant were harvested for Western immunoblot analysis. (B) 2
HIVgpt construct. Transfectants were replated in equal amounts onto three plates and either l
were collected and prepared for Western immunoblot analysis. Cells (4% of total sample
electroblotted onto nitrocellulose ﬁlters. HIV-1 Gag proteins were probed with a mouse mo
monoclonal antibody. Positions of HIV-1 Gag proteins Pr55, p41, and p24 are indicated at leEFV binding to the p66RT Gag–Pol sequence promotes Gag–Pol/Gag–
Pol interactions by enhancing RT–RT interaction, thereby prematurely
activating PR to cleave the Gag precursor and triggering a sharp
reduction in virion release (Figueiredo et al., 2006). If true, mutations
that impair RT–RT interaction may diminish the EFV enhancement
effect on Gag–Pol multimerization, resulting in an attenuated EFV
effect on virus particle production by preventing premature PR-
mediated Gag processing. Accordingly, the effects of Trp repeat motif
mutations on Gag–Pol/Gag–Pol interaction can be better understood
by testing whether or not EFV is capable of modulating virus particle
production subsequent to mutations in the Trp repeat motif.
For this study we analyzed the effects of a double mutation at Trp
residues W401 and W402 on virus assembly, processing, and
infectivity in the presence or absence of EFV. Our results indicate
that these mutations signiﬁcantly impair RT stability and packaging
in a PR activity-dependent manner. Despite having no gross effect on
Gag processing, we found that the W401A/W402A mutations
signiﬁcantly minimize the EFV suppression effect on virus particle
production, suggesting that they impair Gag–Pol/Gag–Pol interaction.
However, we also observed that a single substitution mutation at
W401 resulted in the near-complete elimination of the EFV
inhibitory effect on virus production, strongly suggesting that the
Trp repeat motif contributes to Gag–Pol/Gag–Pol interaction, which
is considered crucial to triggering PR activation. We also found that
an artiﬁcial p66RT (expressed separately from Gag–Pol) carrying the
single W401A mutation or double W401A/W402A mutations was
packaged into VLPs more efﬁciently than wt, but viral incorporationase inhibitor. (A) 293T cells were transfected with wild-type (WT) HIVgpt construct. At
onto four plates, and either treated (+) or mock-treated (−) with 1 μM efavirenz (EFV) or
nd replaced with medium containing the indicated chemicals. At 48 h post-medium
93T cells were transfected with either WT, PR-inactivated D25, or a pol-deleted (Gag)
eft untreated or treatedwith 5 μMor 10 μMEFV. After 48 h, cells and culture supernatant
s) and viral pellets (50% of total samples) were fractionated by 10% SDS-PAGE and
noclonal antibody directed against the p24CA. Panel A, reprobed with an anti-β-actin
ft.
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by the RT-dimerization enhancer EFV. The single exception was the
EFV-resistant mutant L100I/K103N. In addition to suggesting that RT
dimer formation is not necessary for its association with Gag, our
data also reveal a previously unknown EFV effect on the incorpora-
tion of RT into VLPs.
Results
p51RT subunit domain requirement for EFV enhancement effect on HIV-1
Gag processing
To conﬁrm that virus production inhibition by EFV is PR activity-
dependent, we either (a) employed an HIV-1 PR-inactivated or Pol-
devoid expression vector or (b) added a PR inhibitor (PI) post-
transfection. As expected and consistent with previous reports
(Figueiredo et al., 2006), the inhibitoryeffect of EFVonvirus production
was dramatically abrogated in the presence of an HIV-1 PR inhibitor
(panel A) as well as in the absence of a functional PR domain (panel B).
Virion production was not signiﬁcantly affected when treatment
consisted of nevirapine (another NNRTI) (data not shown). Similar to
Gag instability in thepresence of over-expressedPR (Wanget al., 2000),
some EFV-treated samples had slightly reduced levels of cellular Gag
(Fig. 1A, lane 6). It is unlikely that this decrease was the result of
cytotoxicity, since none was observed in either transfected or mock-
transfected cells treated with EFV at the same concentration.Fig. 2. Effect of efavirenz on truncated HIV-1 Gag–Pol mutant assembly and processing. (A)
domains and pol-encoded p6⁎, PR, RT, and IN (p31) are indicated, along with p66RT subdom
numbers indicate IN or RT terminal amino acid residue positions. The ﬁnal 4 residues in each
cells were transfected with designated constructs. At 18 h post-transfection, transfectants we
72 h later, cells and supernatant were harvested and subjected to Western blot analysis asWe previously demonstrated that Gag–Pol truncation mutations
result in reduced PR-mediated Pr55gag processing efﬁciency (Liao and
Wang, 2004). To better understand the contribution of the Pol
sequence to the EFV enhancement effect on Gag processing, a set of
HIV-1 mutants containing various C-terminal truncations in the pol
coding sequence (Fig. 2A) was transiently expressed in 293T cells in
the presence or absence of EFV. Similar to the results observedwithwt
HIV-1, virion levels produced by RN198, R560, and R425 mutants that
retained an intact RT connection subdomain were markedly reduced
by EFV (Fig. 2B, lanes 1–12). In contrast, EFV did not improve the Gag
processing of R305 and R182, both lacking the RT connection
subdomain and therefore considered defective in terms of Gag
processing (lanes 13–18). These results also suggest that the RT
sequence makes a signiﬁcant contribution to PR activation, upon
which the Gag processing-enhancement effect of EFV may depend.
The RN198 mutant showed a greater decrease in steady state levels of
intracellular Gag compared to R560 (lanes 22–27), implying greater
RN198 susceptibility to EFV enhancement.
Tryptophan repeat motif mutations attenuate EFV effect on virus
production
To determine whether mutations at the Trp repeat motif counter-
act the inhibitory effect of EFV on virion production, a double mutant
designated W401A/W402A was constructed by replacing residues
W401 and W402 with alanine. The L100I/K103N EFV-resistant doubleSchematic representations of HIV-1 Gag–Pol truncation mutations. Mature Gag protein
ain boundaries. Numbers refer to amino acid residue positions. Designated construct
truncated construct are shownwith inserted or altered amino acids in boldface. (B) 293T
re replated onto three dish plates and treated with indicated concentrations of EFV. 48–
described in our Fig. 1 legend.
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on Gag processing–served as a control. An unintentionally created
K102N mutant was also included. Since K102 is located next to the
well-documented EFV-resistant K103N mutant (Bacheler et al., 2000),
and since K102N has never been reported as being associatedwith any
EFV-selected mutation, we felt it was of interest to test the effects of
EFV on this mutant. Since the primary EFV effect involves RT activity
inhibition, our control group also included D185A/D186A, a RT-Fig. 3. EFV effect on HIV-1 RTmutant assembly and processing. 293Tcells were transfectedwi
or one of the following RT substitution mutations: L100I/K103N, K102N, W401A/W402A, or D
A) or three (panels B and C) dish plates with or without the addition of EFV. Two days late
analysis. HIV-1 Gag proteins were probed with an anti-p24CA monoclonal antibody. RT and I
Pr160gag–pol; RT p66 and p51 subunits; and Gag Pr55, p41 and p24.inactivated double mutant constructed by replacing the conserved
catalytic Asp residues 185 and 186 (Kohlstaedt et al., 1992) with
alanine residues.
Wt and each of the RT mutants were transiently expressed in 293T
cells. Results from a Western immunoblot analysis of virus particle
assembly and processing indicate that none of the RT mutations had a
major effect on virus assembly and processing—that is, all of the
mutants produced virion levels similar to wt and exhibited steady-th wild-type (WT) ormutant HIVgpt plasmids carrying the D25 PR-inactivatedmutation
185A/D186A. At 18 h post-transfection, transfectants were split equally onto two (panel
r, cells and culture supernatant were collected and subjected to Western immunoblot
N were detected with anti-RT and anti-IN serum, respectively. Indicated are positions of
Fig. 4. Relative reverse transcriptase activity levels of HIV-1 mutants. 293T cells were
transfected with the indicated plasmid. At 48–72 h post-transfection, supernatant was
collected, pelleted, and resuspended in PBS buffer. Equivalent aliquots (panel B) were
left untreated or treated with 1 μM or 5 μMof EFV prior to in vitro RT assays. Ratios of RT
activity to Gag protein levels obtained via immunoblot band density quantiﬁcationwere
determined for each mutant and normalized to those of wt (panel A) or mock-treated
samples (panel B). Values for each construct derived from at least three independent
experiments. Error bars indicate standard deviation.
Fig. 5. Infectivity of virions produced from transfected cells treated with or without EFV.
293T cells were transfected with the indicated plasmid plus a VSV-G expression vector.
At 4 h post-transfection, transfectants were replated on two dish plates and either left
untreated or treated with 1 μM EFV. Two days later, about 60% of the collected
supernatant was subjected to Western immunoblot analysis. Remaining supernatants
were serially diluted and used to infect HeLa cells. Infection and selection of drug-
resistant cell colonies were performed as described in Materials and methods. Drug-
resistant colonies were converted to titers (infectious units/ml). Rations of viral titers to
Gag protein levels obtained via immunoblot band density quantiﬁcation were
determined for each mutant and normalized to those of wt in parallel experiments.
Error bars indicate standard deviation.
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panel). When treated with 1 μM EFV (which markedly suppressed wt
and D185A/D186A viral production; lanes 9 and 13), quantities of
virions produced by W401A/W402A were only moderately reduced
(lane 12), suggesting that the W401A/W402A mutations partially
counteracted the EFV effect. In the case of L100I/K103N and K102N,
both were still capable of producing substantial amounts of virions
(lanes 10–11). Note that the W401A/W402A mutant expressed low
levels of steady-state RT subunits in both virions and cell lysates (lanes
5 and 19). Since IN was still readily observed (Fig. 3A, lane 5), the
difﬁculty in detecting W401A/W402A RT was likely the result of the
mutation's susceptibility to PR-mediated degradation as a conse-
quence of its inability to form a stable RT heterodimer. However, since
IN levels in W401A/W402A virions were noticeably reduced com-
pared to wt, we cannot exclude the possibility that these mutations
also exerted an effect on Gag–Pol stability, one that could not be
detected in terms of an increase in the ratio of virion Pr55gag to p24gag.
The above results suggest that even as small an amount as 1 μM of
EFV is sufﬁcient to inhibit wt virus production. According to the results
of our tests using higher concentrations of EFV, no major effect was
noted on L100I/K103N viral production (Fig. 3B, lanes 7–9), indicating
that the EFV-resistant mutations negated the EFV enhancement effect
on Gag processing. In contrast, virion quantities produced by K102N
were markedly reduced when EFV concentration was increased to
5 μM (lanes 10–12).We also observed that Gag precursors representedthe major Gag species in W401A/W402A medium samples following
treatment with higher doses of EFV (Fig. 3C, lanes 4–6), suggesting
W401A/W402A resistance to the EFV enhancement effect on Gag
processing. It is unlikely that EFV has a direct inhibitory effect on
W401A/W402AGag processing, since the blocking of PR activity in the
context of W401A/W402A resulted in increased rather than decreased
viral production (data not shown). A more likely explanation is that
the W401A/W402A mutation induced a conformational change that
either affected EFV binding and/or impaired Gag–Pol/Gag–Pol inter-
actions after EFV binding, resulting in failure to acquire a fully
activated PR to efﬁciently process Pr55gag.
To assess RT activity for each mutant, aliquots of resuspended viral
pellets were subjected to in vitro RT activity assays. The results shown
in Fig. 4A indicate a background level of RT activity for the W401A/
W402A mutant, which is compatible with its barely detectable virus-
associated RT (Fig. 3A, lane 5). As expected, the D185A/D186A
mutations effect an almost complete elimination of RT activity. The
EFV-resistant mutant L100I/K103N showed signiﬁcantly reduced RT
activity at about 50% of the wt level, but no major effect on RT activity
was noted for the K102Nmutant. The PR-inactivatedmutants D25 and
D25(L100I/K103N) exhibited RT activity at about 50–70% that of wt,
suggesting that the Gag–Pol precursors still possess signiﬁcant in vitro
RT polymerase activity.
To conﬁrm that L100I/K103N confers resistance to the EFV
inhibitory effect on RT, aliquots containing equivalent amounts of
virions were either left untreated or treated with 1 μM or 5 μM of EFV
prior to in vitro RT assays. Results indicate that EFV signiﬁcantly
inhibited both wt and K102N RT activity to similar extents under the
same conditions, suggesting that the K102N mutation confers little if
any resistance to the EFV effect on RT activity (Fig. 4B). Conversely,
L100I/K103N RT activity in either a mature form or Gag–Pol context
[D25(L100I/K103N)] was not signiﬁcantly affected by EFV.
A single-cycle infection assay was performed to test the effects of
EFV on the production of infectious virions. The results presented in
Fig. 5 indicate that wt viral infectivity was reduced approximately
twenty-fold by 1 μM EFV, presumably due to EFV inhibition of both
virion release and RT activity. In contrast, L100I/K103N infectivity was
lower than that of wt, regardless of EFV treatment or lack of it. K102N
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the addition of 1 μM EFV. As expected, W401A/W402A infectivity was
weak. In general, our infectivity assay results are compatible with our
in vitro RT activity assay results.
W401A/W402A RT instability is PR activity-dependent
The data shown in Fig. 3 suggest that theW401A/W402Amutation
speciﬁcally impairs RT stability. To determine any connection betweenFig. 6.W401A/W402A RT mutant instability is HIV-1 protease activity-dependent. (A) 293T c
were replated onto four dish plates and either left untreated or treated with HIV-1 protease i
coding HA-tagged wt or mutant p66RT plus either a wild-type or PR-inactivated (D25) HIVg
culture supernatant were collected, prepared, and subjected toWestern immunoblot analysi
p24gag are indicated. Panel B arrowhead indicates HA-tagged p66RT position, which migratRT instability/degradation and viral protease activity, W401A/W402A
transfectants were treated with an HIV-1 PR inhibitor (PI). When PI
concentrations were gradually increased, virus-associated W410A/
W402A RT products that were previously undetectable or barely
detectable (i.e., subunits p66 and p51 and RT-associated precursors
including Pr160gag–pol) became readily detectable (Fig. 6A, lanes 6–
9). This supports our hypothesis that W401A/W402A RT degradation
is primarily mediated by viral PR. However, virus-associated RT
molecules in W401A/W402A medium samples (Fig. 6A, lines 7 and 9)ells were transfected with wt or mutant HIVgpt plasmids. At 4 h post-transfection, cells
nhibitor at the indicated concentration. (B) 293T cells were cotransfected with a plasmid
pt plasmid or a Pr55gag (Gag) expression vector. At 48–72 h post-transfection, cells and
s. Positions of Pr160gag–pol, wt or HA-tagged p66/p51 RT subunits, IN, Pr55gag, p41gag, and
ed more slowly than its untagged counterpart (lane 1).
Fig. 7. EFV effect on HIV-1 virion production. 293T cells were transfected with wt or
mutant HIVgpt. At 4 h post-transfection, transfectants were replated onto three dish
plates and either left untreated or treated with 5 μM or 10 μM EFV. Two days later,
culture supernatant and cells were harvested, prepared, and subjected to Western
immunoblot analysis. HIV-1 Gag and RT proteins were probed with anti-p24CA and
anti-RT monoclonal antibodies, respectively.
267C.-C. Chiang et al. / Virology 383 (2009) 261–270showed in vitro RT activity at about background level (data not
shown), suggesting that the W401A/W402A mutations markedly
impair RT polymerase activity.
To further test whether W401A/W402A affects RT stability outside
of a Gag–Pol context, we inserted W401A/W402A into an HA-tagged
p66RT subunit expression vector. The resulting construct, designated
HA-p66(WA/AA), was coexpressed with virus-producing vectors. Our
results indicate that the HA-p66RT construct can be packaged into
virus-like particles (VLPs) (Fig. 6B, lanes 5 and 6), which is consistent
with previous ﬁndings (Liao et al., 2007). Also readily observed was a
band corresponding to HA-p51RT derived from a trans cleavage of HA-Fig. 8. Incorporation of p66RT into virus-like particles. 293T cells were cotransfected with a P
mutant containing theW401A (W/A), W401A/W402A (WW/AA), or L100I/K103N (LI/KN)mut
(panel B) dish plates. Transfectants were either left untreated or treated with EFV at the ind
collected, prepared, and subjected toWestern blot analysis. HIV-1 Gag and RT were detected
mutant p66RT proteins were quantiﬁed by scanning Pr55gag and p66RT band densities from i
wt samples (lane 1). Relative levels of VLP-associated p66RT are indicated at bottom of ﬁgup66RT by the coexpressed wt PR (lane 4, top panel). In contrast, virus-
associated HA-p66(WW/AA) was barely detected in wt cotransfection
samples, even though it can be efﬁciently packaged into VLPs devoid
of PR activity (lanes 1–3, top panel). We noted a wt p66RT subunit
migrating slightly faster than the HA-p66RT (Fig. 6B, lane 1, middle
panel). While on some occasions intracellular p51 was barely
detected, we consistently detected virus-associated (HA)-p51RT in
repeat experiments. Combined, the data give strong support to our
proposal that W401A/W402A RT instability and degradation is PR
activity-dependent.
W401A negates EFV inhibitory effect on virion production
Since the W401A mutation has been reported as markedly
impairing RT dimerization (Mulky et al., 2005; Tachedjian et al.,
2003; Wapling et al., 2005), we tested its ability to nullify the EFV
enhancement effect on Gag processing. Our results indicate that the
W401A mutation confers strong resistance to this effect, to an extent
similar to that of L100I/K103N. Virions produced byW401Awere only
moderately affected when EFV concentration was increased to 10 μM
(Fig. 7). Similar to W401A/W402A, the W401A mutant had low
infectivity and exhibited RT activity at approximately background
level (data not shown), despite containing detectable amounts of RT
(Fig. 7, lanes 4–6); this ﬁnding is consistent with those from a previous
report (Wapling et al., 2005).
EFV reduces p66RT viral incorporation efﬁciency
Compared with wt p66, p66(WW/AA) showed higher viral
incorporation efﬁciency (Fig. 6B, lanes 2–3 vs. 5–6). This was an
unexpected result, since it suggests that putative dimerization-
defective mutants will associate with Gag more efﬁciently than with
wt. The result also implies that enhanced dimerization by EFV may
reduce RT viral incorporation efﬁciency. To test this possibility, p66RT
wt or a mutant carrying W401A (W/A), W401A/W402A (WW/AA) or
L100I/K103N (LI/KN) was coexpressed with Pr55gag in the presence orr55gag expression vector and a plasmid encoding HA-tagged HIV-1 p66RT—either wt or a
ation. At 4 h post-transfection, equal cell quantities were placed on four (panel A) or two
icated concentration. At 48–72 h post-transfection, cells and culture supernatant were
with anti-p24CA and anti-HA monoclonal antibodies, respectively. HIV-1 Gag and wt or
mmunoblots. Ratios of RT to Gag were determined and normalized to those of untreated
re.
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was signiﬁcantly reduced by EFV in a dose-dependent manner
(Figs. 8A, lanes 1–4 and B, lanes 1–2). The packaging efﬁciencies of
p66(W/A) and p66(WW/AA) were also noticeably reduced by EFV
(Fig. 8B, lanes 3–6). In contrast, and compatible with the L100I/K103N
mutational effect on conferring EFV resistance, EFV had virtually no
negative effect on p66(LI/KN) packaging (Figs. 8A, lanes 5–8, and B,
lanes 7–8). Combined, these results suggest that efﬁcient RT
dimerization is not required for RT association with Gag, and that
EFV binding with RT may interfere with that association.
Discussion
Our ﬁnding that EFV signiﬁcantly inhibits HIV-1 virion production
via enhanced PR-mediated Gag processing is consistent with previous
reports (Figueiredo et al., 2006). However, the EFV-mediated
enhanced processing of Pr55gag to p24gag in cell lysates reported by
Figueiredo et al. (2006) was not observed (Fig. 1B, lanes 14 and 15). A
possible explanation is the difference in the timing of cell harvesting
post-EFV treatment: Figueiredo et al. collected cells at 36 h and we
collected them at 48 h. That is, we collected cells when the level of
newly synthesized Pr55gag was approximately equal to that of
processed p24gag.
Given that Gag–Pol/Gag–Pol interactions are required for trigger-
ing PR activation to mediate virus processing, mutations that affect
RT–RT interactions can indirectly impair PR-mediated Gag processing
by impairing Gag–Pol/Gag–Pol interaction. However, Trp repeat motif
mutations that impair HIV-1 RT dimerization (Mulky and Kappes,
2005; Tachedjian et al., 2003) apparently do not exert signiﬁcant
effects on steady-state Gag processing (Wapling et al., 2005).
Furthermore, results from our co-immunoprecipitation experiments
suggest that interaction efﬁciency between HA-tagged p66 W401A/
W402A RT and myc-tagged p66 W401A/W402A RT was lower
compared to that of wt interaction. TheW401Amutation hadminimal
effect on RT–RT interaction (data not shown). This is inconsistent with
previous reports indicating that the W401A mutation signiﬁcantly
affects recombinant RT dimerization expressed in bacteria (Tachedjian
et al., 2003, 2005b). It may be that somemammalian factors in our co-
immunoprecipitation experiments facilitated the dimerization of the
W401A mutant, leading to a different observation.
It is also possible that interactions between RT molecules may
undergo considerable change when they occur in a Gag–Pol context,
especially since Gag–Pol multimerization is largely determined by the
N-terminal Gag domain (Liao and Wang, 2004). However, subtle
effects from these mutations on Gag–Pol/Gag–Pol interactions
associated with PR activationwere observed following EFV treatment.
The data shown in Figs. 3 and 7 suggest that even though bothW401A
and W401A/W402A mutations do not signiﬁcantly affect steady-state
Gag processing, they may inﬂuence Gag–Pol/Gag–Pol interaction to a
degree that prevents EFV-bound Gag–Pol molecules from interacting
as required for PR activation.
Diminished susceptibility to the effects of EFV incurred by the
W401A and W401A/W402A mutations may be due to a defect in EFV
binding to Gag–Pol. However, it has been suggested that EFV binds to
p66RT in the Gag–Pol context (Tachedjian et al., 2005a), and several
research teams have posited that the W401A or W401A/W402A
mutation does not signiﬁcantly affect the binding of EFV to Gag–Pol.
Some argue that the crystal structure of NNRTI-bound RT indicates
that the Trp repeat motif does not belong to residues constituting the
NNRTI-binding pocket (Hsiou et al., 1996; Sluis-Cremer et al., 2004).
Others point to in vitro study results suggesting that EFV is in fact
capable of enhancing the self-association of dimerization-defective
W401A RT to a limited extent (Tachedjian et al., 2001). In addition, EFV
noticeably affects the viral incorporation of wt or mutant p66RT
carrying the W401A/W402A or W401A mutations (Fig. 8), and
substitute mutations at residues L100/K103 situated at the entranceof the NNRTI-binding pocket negate the inhibitory effect of EFV on RT
polymerase activity in both mature RT form and Gag–Pol contexts
(Fig. 4). Furthermore, we failed to ﬁnd any adverse effect of EFV on the
viral incorporation of the L100I/K103N RT mutant (Fig. 8). Combined,
the data strongly suggest that Gag–Pol and p66RT share a major EFV-
binding domain, and that the Trp repeat region is not directly involved
in EFV binding.
We therefore suggest that diminishedW401A/W402A andW401A
susceptibility to the effects of EFV on virus production is most likely
due to a defect in Gag–Pol/Gag–Pol interactions that impedes EFV
enhancement of Gag–Pol multimerization and consequently prevents
PR-mediated Gag cleavage. Assuming that proper Gag–Pol/Gag–Pol
interactions are required for Gag–Pol RT polymerase activity (D25,
Fig. 4), data showing that both W401A and W401A/W402A virus-
associated Gag–Pol exhibit poor RT activity in the presence of a PR
inhibitor (data not shown) support our hypothesis that the two
mutations signiﬁcantly impair Gag–Pol/Gag–Pol interactions.
Although treatment with a higher concentration of EFV markedly
inhibited virion release, the majority of virions produced by W401A/
W402A were incompletely processed (Fig. 3). This is similar to PR
activity-deﬁcient Gag–Pol—when over-expressed it can signiﬁcantly
reduce virion release, and most of the released virions are incomple-
tely processed (Chen et al., 2004). This implies a minor defect in
W401A/W402A in terms of Gag–Pol/Gag–Pol interaction, thus block-
ing full PR activation following EFV treatment.
Alternatively, excessive free or Gag–Pol-associated EFV molecules
may affect Gag–Pol multimerization, especially at higher concentra-
tions. This idea is supported by the ﬁnding that a faint band
corresponding to Pr55gag was detected in wt viral samples when
treated with 5 μM EFV (Fig. 3B, lane 3). In contrast, mature p24gag was
predominant in virions produced by the mutant K102N; note that
virion quantities were signiﬁcantly reduced when EFV concentration
was increased (Fig. 3B, lane 12). Also, whereas treatment with 1 μM
EFV had a strong effect on K102N RT activity and infectivity, it had no
major effect on K102N virus production. These data suggest that
K102N confers partial resistance to the EFV enhancement effect on
Gag processing, and that the drug level required to achieve a
noticeable reduction in virion release is higher than the level required
to inhibit RT activity and viral infectivity. The combination of K103N
and L100I mutations has been found to reduce EFV susceptibility by
over 100-fold (Rhee et al., 2006), although the replication efﬁciency or
ﬁtness of L100I/K103N is signiﬁcantly reduced (Koval et al., 2006).
These data are consistent with our observations for L100I/K103N,
which is highly EFV-resistant but possesses lower infectivity com-
pared to wt.
Our ﬁnding that EFV is capable of signiﬁcantly reducing p66RT
viral incorporation (Fig. 8) suggests that EFV may interfere with RT–
Gag interaction and/or that EFV-bound RT is incapable of efﬁcient
association with Gag. This represents a previously unreported EFV
effect, the signiﬁcance of which remains to be determined. During
HIV-1 replication, it is generally believed that HIV-1 Gag is still
associated with reverse transcriptional machinery following viral
entry. As a pre-integration complex component, Gag proteins–
especially MA and NC–are both functionally involved in viral reverse
transcription or integration (Buckman et al., 2003; Bukrinsky et al.,
1993; Carteau et al., 1997; Casella et al., 1997; Kiernan et al., 1998; Yu et
al., 1992). However, it is unknown whether EFV affects interactions
between RT and mature Gag proteins. Since RT–Gag interactions are
strongly affected by EFV at a dose (0.1 μM) far below that of mean
plasma EFV concentrations (7 μM) in HIV-1-infected individuals
receiving EFV treatment protocols (Marzolini et al., 2001), it is
tempting to speculate about whether EFV tethers PIC functions by
modulating Gag–RT interactions. In other words, in addition to
inhibiting RT polymerase activity and virus particle production, EFV
may block viral replication by means of an additional undeﬁned
mechanism, possibly by disrupting RT association with Gag.
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Plasmid construction
The parental HIV-1 proviral plasmid used in this study was
derived from HXB2. DNA fragments containing the engineered RT
mutations were generated by PCR-based overlap extension muta-
genesis using HIVgpt as a template. Primers for RT mutation
construction were 5′-GAAACATGGGAAACCGCGGCGACAGAGTAT-3′
(forward) and 5′-GAAATTGGATCCATTGGCAGTATGTATTG-3′ (reverse) for
W401A/W402A; 5′-GGATTAGATATCAGTACAATG-3 (forward) and 5′-
CCTACATACAGCGCTGCCATGTATTGATA-3′ (reverse) for D185A/
D186A; 5′-CATCCCGCCGGCATAAAAAAGAACAAATCAGTA-3′ (forward)
and 5′-ATGTATGGATCCATAACTAT-3′ (reverse) for L100I/K103N; and
5′-CCCGCAGGGCTTAAGAACAAAAAATCAGTA-3′ (forward) and 5′-
ATGTATGGATCCATAACTAT-3′ (reverse) for K102N. Resulting ampli-
cons served as primers for a second PCR round using either the
forward primers 5′-AATGATGCAGAGAGGCAAT-3′ or 5′-GGATTAGA-
TATCAGTACAATG-3, or the reverse primer 5′-GAAATTGGATCCATTGGCAG-
TATGTATTG-3′. Ampliﬁed DNA fragments were digested with a
combination of either EcoRV and BglII or EcoRV and BsrGI and
ligated into HIVgpt. HIV-1 Pol-truncated mutants (RN198, R560,
R425, R305, R182) containing inserted stop codons at the designated
IN or RT residue positions and plasmids expressing RT subunits p66
and p51 containing HA tags at the N-terminus were as described
previously (Liao et al., 2007; Liao and Wang, 2004). The HIV-1
Pr55gag-expression plasmid pGAG and the PR-inactivated mutant
HIVgpt D25 have also been described previously (Chiu et al., 2002;
Wang et al., 2000).
Cell culture, transfection, and infection
293Tcells and HeLa cells weremaintained in DMEM supplemented
with 10% fetal calf serum. Conﬂuent 293T cells were trypsinized, split
1:10, and seeded onto 10 cm dish plates 24 h before transfection. For
each construct, 293T cells were transfected with 20 μg of plasmid DNA
by the calcium phosphate precipitation method, with the addition of
50 μm chloroquine to enhance transfection efﬁciency. For infection,
10 μg of wt or mutant HIVgpt were cotransfected with 5 μg of the VSV-
G protein expression vector pHCMV-G (Burns et al., 1993). At 48 h
post-transfection, virus-containing supernatant was collected, ﬁl-
tered, andmixed with 4 μg/ml polybrene to infect HeLa cells. After 16–
18 h, cells were trypsinized, split into dishes and refed with medium
containing drug selection cocktail (Chen et al., 1997). Selected
mycophenolic acid-resistant colonies were ﬁxed and stained with
50% methanol containing 0.5% methylene blue. Numbers of drug-
resistant colonies were converted into titers (cfu/ml). Infectivity was
expressed as the ratio of the mutant titer to the titer of wt in parallel
experiments.
Western immunoblot analysis
Culture media from transfected 293T cells was ﬁltered (0.45 μm
pores) and centrifuged through 2 ml of 20% sucrose in TSE (10 mM
Tris–HCl [pH 7.5], 100 mM NaCl, 1 mM EDTA) plus 0.1 mM
phenylmethylsulfonyl ﬂuoride (PMSF) at 4 °C for 40 min at
274,000 ×g (SW41 rotor at 40,000 rpm). Viral pellets were suspended
in IPB (20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 0.1% SDS,
0.5% sodium deoxycholate, 1% Triton X-100, 0.02% sodium azide) plus
0.1 mM PMSF. Cells were rinsed with ice-cold PBS, scraped from each
plate, collected in 1 ml PBS, and pelleted at 2500 rpm for 5 min. Cell
pellets were resuspended in 250 μl of IPB plus 0.1 mM PMSF, then
subjected to microcentrifugation at 4 °C for 15 min at 13,700 ×g
(14,000 rpm) to remove cell debris. Either supernatant or cell samples
were mixed with equal volumes of 2× sample buffer (12.5 mM Tris–
HCl [pH 6.8], 2% SDS, 20% glycerol, 0.25% bromophenol blue) and 5% β-mercaptoethanol and boiled for 5 min. Samples were subjected to
SDS-PAGE and electroblotted onto nitrocellulose membranes blocked
with 3% gelatin in Tris-buffered saline containing 0.05% Tween 20
(TBST), followed by incubation with the primary antibody in 1%
gelatin-TBST for 1 h on a rocking platform at room temperature.
Membranes were then washed three times for 10 min each with TBST
and rocked for 30minwith the secondary antibody in 1% gelatin-TBST.
Blots were againwashed three times in TBST for 10min each, followed
by enhanced chemiluminescence (ECL) to detect membrane-bound
antibody-conjugated enzyme activity.
HIV Gag protein detection was performed using an anti-p24gag
(mouse hybridoma clone 183-H12-5C) monoclonal antibody at a
1:5000 dilution of ascites. Cellular β-actinwas detected using amouse
anti-β-actin monoclonal antibody (Sigma), also at a 1:5000 dilution.
Primary antibodies for HIV-1 RT or HA-tagged RT detection were
rabbit antiserum, mouse anti-RT (Ferris et al., 1990; Hizi et al., 1988),
or anti-HA (Sigma). Rabbit antiserum served as the primary antibody
for HIV-1 IN detection (Grandgenett and Goodarzi, 1994); our
secondary antibody was either a rabbit anti-mouse or donkey anti-
rabbit (HRP)-conjugated antibody at 1:15,000 or 1:5000 dilution.
Manufacturer's protocols were followed for HRP activity detection
(Pierce).
In vitro RT assay
The procedure used for this study has been described previously
(Chiu et al., 2002). Brieﬂy, transfected 293T cell culture supernatant
was harvested, ﬁltered, and pelleted as described for our Western
immunoblot analysis. After serially diluting viral pellets suspended in
TSE, 10 μl of diluted sample was mixed with 40 μl of reaction cocktail
containing 0.1% Triton X-100, 5 mM dithiothreitol, 10 mM MgCl2,
50 mM Tris–HCl (pH 8.0), 1.2 mM poly(rA)-(dT)15 (Invitrogen), and
25 μCi of [3H]TTP perml. Reactionmixtureswere incubated at 37 °C for
2 h, followed by the addition of 5 μl tRNA (10 mg/ml). Reaction
mixtures were precipitated with ice-cold 10% trichloroacetic acid and
ﬁltered through CF/C ﬁlters. After washing and drying, RT activity was
determined using a Beckman scintillation counter.
Coimmunoprecipitation assay
293T cells transfected with HA-tagged and/or Myc-tagged p66RT
expression vector were collected, lysed in RIPA buffer (140 mM NaCl,
8 mM Na2HPO4, 2 mM NaH2PO4, 1% NP-40, 0.5% sodium deoxycho-
late, 0.05% SDS) containing complete protease inhibitor cocktail
(Roche), and microcentrifuged at 4 °C for 15 min at 13,700 ×g
(14,000 rpm) to remove cell debris. Aliquots of post-nuclear super-
natant (PNS) were mixed with equal amounts of 2× sample buffer and
5% β-mercaptoethanol and held for Western blot analysis. RIPA buffer
was added to the remaining PNS samples to ﬁnal volumes of 500 μl.
Each sample was mixed with an anti-HA monoclonal antibody (1:500
dilution) and 20 μl of protein G agarose. All reactions took place at
4 °C overnight on a rocking mixer. Immunoprecipitate-associated
agarose beads were pelleted, washed tree times with RIPA buffer,
washed two times with PBS, eluted with 1× sample buffer with 5% β-
mercaptoethanol, boiled for 5 min, and subjected to SDS-10% PAGE as
described above.
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